Shanghai Jemincare Pharmaceuticals Co., Ltd.

Jiangxi Jemincare Group Co., Ltd.

Janssen Pharmaceutica Nv

Novartis Ag

Genentech, Inc.

China Novartis Institutes for Biomedical Research Co., Ltd.

Haibing Guo

Jianbiao Peng

Qian Liu

Zhao-Kui Wan

Weiqiang Xing

Luoheng Qin

Hongfu Lu

Shuchun Guo

Wing Shun Cheung

Baojian Qi

Yang Liu

Chao Chen

Feng He

Lei Jiang

Yuan Mi

Fang Liang

Hongping Yu

Haibing Deng

Yao-Chang Xu

Huixin Wan

Yongcong Lv

Pierre Jean-Marie Bernard Raboisson

Abdellah Tahri

Hui Li

Koen Vandyck

Jun Zhu

Qiong Zhang

Ji Yue Zhang

Jun Fan

Ji Yue (Jeff) Zhang

Fang Bao

Chunliang Lu

Kun Chin Liu

Jiangwei Wang

Yihui Zhu

Zhuming Sun

Zhenting Gao

Shan Yao

Zhangping Kang

Yan Ye

Kevin Kun Chin Liu

Yong Zhang

Ming Li

Kevin Kun Liu

Provided are a protein degradation agent compound preparation method and application; specifically, provided are the compound represented by formula (I) and a pharmacologically acceptable salt thereof, and an application of said compound in the degradation of androgen receptor (AR).

Protein degradation agent compound preparation method and application

The invention relates to new thienopyridinone compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds as FGFR (fibroblast growth factor receptor) inhibitors and to their use in the treatment of diseases, e.g. cancer.

Thienopyridinone compounds

The present invention provides a compound of Formula (I): or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by mixed lineage leukemia 1 (MLL1).

MLL1 inhibitors and anti-cancer agents

Disclosed are a phthalazinone compound, and a preparation method therefor and the medical use thereof. In particular, disclosed are a compound as represented by formula (I), and a pharmacodynamically acceptable salt, and the use of the compound as an androgen receptor (AR) for degradation.

Phthalazinone compound, and preparation method therefor and medical use thereof

Relating to a compound represented by formula (I) and a pharmaceutically acceptable salt of the compound, and an application of the compound as an S1P1 agonist.

Aromatic ring derivative as immunoregulation and preparation method and application of aromatic ring derivative

Disclosed in the present invention are a fused pyridone compound, and a preparation method therefor and a use thereof. Specifically, the present invention discloses a compound of formula (I-B), an optical isomer thereof and a pharmaceutically acceptable salt thereof, and the use of the compound as a KRAS inhibitor.

Fused pyridone compound, and preparation method therefor and use thereof

Pyrazolopyridinone compounds, the pharmaceutical compositions comprising said compounds, and the use of said compounds as FGFR (fibroblast growth factor receptor) inhibitors and their use in the treatment of diseases, e.g. cancer.

Pyrazolopyridinone compounds

A compound represented by formula (I), an optical isomer thereof and a pharmaceutically acceptable salt thereof, as well as an application of said compound as an FXIa inhibitor. 

Tricyclic compound, preparation method therefor and use thereof

Provided are a compound of formula (I), an optical isomer thereof, a pharmaceutically acceptable salt thereof, uses of said compound acting as a STING agonist. 

Cyclic dinucleotide compound and uses thereof

The invention relates to new quinolinone compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds as FGFR (fibroblast growth factor receptor) inhibitors and to their use in the treatment of diseases, e.g. cancer.

Quinolinone compounds

Potent 5-HT2B antagonist of Formula (A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof and their use wherein R1 to R4 and Ar have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them, alone or in combination with other drugs, in fibrosis and/or cirrhosis prevention or therapy. 

Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis

The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

Triazolopyridine compounds

Growing community of inventors

Shanghai, China

Haibing Guo